By Christy Santhosh and Puyaan Singh (Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker ...

Rinvoq to $31B amid Humira decline. Skyrizi hit $11.7B and Rinvoq $5.97B in 2024, while Humira fell to $9B from $14.4B in 2023.

AbbVie shares surged nearly 8% Friday morning, after the company substantially raised its sales forecasts for two key drugs. While reporting fourth-quarter revenue and earnings per share above Wall ...

Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter ...

As its shares pop in Friday's session, pharmaceutical giant AbbVie Inc. (ABBV) posted a fourth quarter revenue beat and ...

The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...

Says well-positioned with ex-Humira platform for 2025. Sees clear runway for growth “for at least eight years.” Expects Skyrizi and Rinvoq to ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...